↓ Skip to main content

Prophylactic treatment of vestibular migraine

Overview of attention for article published in Brazilian Journal of Otorhinolaryngology, June 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
34 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prophylactic treatment of vestibular migraine
Published in
Brazilian Journal of Otorhinolaryngology, June 2016
DOI 10.1016/j.bjorl.2016.04.022
Pubmed ID
Authors

Márcio Cavalcante Salmito, Juliana Antoniolli Duarte, Lígia Oliveira Golçalves Morganti, Priscila Valéria Caus Brandão, Bruno Higa Nakao, Thais Rodrigues Villa, Fernando Freitas Ganança

Abstract

Vestibular migraine (VM) is now accepted as a common cause of episodic vertigo. Treatment of VM involves two situations: the vestibular symptom attacks and the period between attacks. For the latter, some prophylaxis methods can be used. The current recommendation is to use the same prophylactic drugs used for migraines, including β-blockers, antidepressants and anticonvulsants. The recent diagnostic definition of vestibular migraine makes the number of studies on its treatment scarce. To evaluate the efficacy of prophylactic treatment used in patients from a VM outpatient clinic. Review of medical records from patients with VM according to the criteria of the Bárány Society/International Headache Society of 2012 criteria. The drugs used in the treatment and treatment response obtained through the visual analog scale (VAS) for dizziness and headache were assessed. The pre and post-treatment VAS scores were compared (the improvement was evaluated together and individually, per drug used). Associations with clinical subgroups of patients were also assessed. Of the 88 assessed records, 47 were eligible. We included patients that met the diagnostic criteria for VM and excluded those whose medical records were illegible and those of patients with other disorders causing dizziness and/or headache that did not meet the 2012 criteria for VM. 80.9% of the patients showed improvement with prophylaxis (p<0.001). Amitriptyline, Flunarizine, Propranolol and Topiramate improved vestibular symptoms (p<0.001) and headache (p<0.015). The four drugs were effective in a statistically significant manner. There was a positive statistical association between the time of vestibular symptoms and clinical improvement. There was no additional benefit in hypertensive patients who used antihypertensive drugs as prophylaxis or depressed patients who used antidepressants in relation to other prophylactic drugs. Drug association did not show statistically significant results in relation to the use of a single drug. Prophylactic medications used to treat VM improve the symptoms of this disease, but there is no statistically significant difference between the responses of prophylactic drugs. The time of vestibular symptom seems to increase the benefit with prophylactic treatment.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 34 100%

Demographic breakdown

Readers by professional status Count As %
Other 5 15%
Student > Master 5 15%
Student > Bachelor 4 12%
Student > Doctoral Student 3 9%
Researcher 2 6%
Other 4 12%
Unknown 11 32%
Readers by discipline Count As %
Medicine and Dentistry 14 41%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Nursing and Health Professions 2 6%
Biochemistry, Genetics and Molecular Biology 1 3%
Neuroscience 1 3%
Other 2 6%
Unknown 12 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 June 2016.
All research outputs
#20,656,161
of 25,373,627 outputs
Outputs from Brazilian Journal of Otorhinolaryngology
#501
of 726 outputs
Outputs of similar age
#270,047
of 353,819 outputs
Outputs of similar age from Brazilian Journal of Otorhinolaryngology
#17
of 35 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 726 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,819 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.